What's new

Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised

Jun 16, 2025 - 16:25
 0
Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

7ff: Revolutionizing Online Gaming with Innovation and Reliability

Next Article

Human medicines European public assessment report (EPAR): Spevigo, spesolimab, D...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Jyseleca, filgotinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0119/2024

Opinion/decision on a Paediatric investigation plan (PI...

Jun 12, 2025  0

EMEA-003552-PIP01-23

EMEA-003552-PIP01-23

Jun 11, 2025  0

Human medicines European public assessment report (EPAR): Dexdor, dexmedetomidine, Date of authorisation: 15/09/2011, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 11, 2025  0